Measurements of complement factor H-related protein (BTA-TRAK (TM) assay) and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary bladder cancer? by Mahnert, Brigitte et al.
Clin Chem Lab Med 2003; 41(1):104–110 © 2003 by Walter de Gruyter · Berlin · New York
Brigitte Mahnert1, Stephan Tauber2, Martin
Kriegmair2, Dorothea Nagel1, Stefan Holdenrieder1,
Karin Hofmann1, Wolfgang Reiter1, Nikolaus
Schmeller2 and Petra Stieber1*
1 Institute of Clinical Chemistry,
2 Urological Department,
University of Munich, Munich, Germany
Between 1997 and 2000 we investigated in a prospec-
tive study the voided urine samples of all consecutive
patients undergoing cystoscopy independent from
their clinical background (n = 705) with the BTA-TRAK™
assay (Bard Diagnostics, Redmont, USA) detecting a
complement factor H-related protein (CFHrP) and the
NMP22 assay (Matritech, Newton, USA) measuring a
nuclear matrix protein, which is supposed to be specific
for bladder cancer. The individuals were divided into
three groups concerning the clinical background: 233
patients had urological diseases, 268 patients had uri-
nary bladder cancer and 150 patients had other urologi-
cal malignancies. Based on the clinical findings we com-
pared our results with well established diagnostic
methods for urinary bladder cancer such as cytology
and the detection of hematuria. In addition, we investi-
gated urine samples from 30 healthy individuals and 24
patients with urinary tract infection without perform-
ing cystoscopy. Following the recommendations of the
European Group on Tumor Markers we used 95% speci-
ficity for benign urological diseases and urinary tract in-
fections, which resulted in a sensitivity of 17% for active
bladder cancer for the BTA-TRAK™ assay and 31% for
NMP22. We compared these results with the detection
of hematuria (specificity: 72%) and cytology, which had
a sensitivity of 64% and 89%, respectively. Subse-
quently, we calculated sensitivity and specificity for the
detection of relapse of the disease. Again using 95%
specificity, in this case for patients with no evidence of
disease (NED), in patients with recurrent disease the
BTA-TRAK™ assay showed 8% sensitivity as compared
to 12% for the NMP22 assay. Due to an insufficient
specificity and sensitivity, both tests can neither be clin-
ically useful in screening of high risk patients, nor in pri-
mary diagnosis of bladder cancer. They cannot replace
neither cystoscopy nor cytology. In the follow-up care
more investigations may be necessary to prove the
benefit of existing diagnostic strategies for the discrim-
ination between active and inactive bladder cancer. Clin
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Introduction
Bladder cancer is the most common tumor of the defer-
ent urinary tract corresponding to 2–3% of all malig-
nant tumors. The male to female ratio is 3:1. The annual
incidence of this disease amounts to approximately
20/100000 inhabitants, the death rate accounts for 5000
individuals per year in Germany. The major problem
caused by bladder cancer is the recurrent disease. It is
vitally important to detect bladder cancer at an early
stage of disease (pTa-pT1 according to TNM staging fol-
lowing the UICC-classification) as once it grows inva-
sive (pT2-4, N1-3, M1) the prognosis of the 5-year sur-
vival decreases from 65–79% to 40–0% (1). Between 50
and 80% of the patients with superficial bladder cancer
will relapse within the first year (2–4). In up to 80% of
patients the most prominent and initial symptom is
hematuria (5). In case of suspicious symptoms cys-
toscopy is performed, which includes exfoliative uri-
nary or irrigation cytology. Currently, for primary diag-
nosis as well as for follow-up care only the invasive
technique of cystoscopy is helpful. Additionally, in
most cases patients undergo irrigation cytology to
search for superficial and not visible bladder cancer. So,
firstly, a non-invasive sensitive method would be desir-
able to replace cystoscopy and, secondly, a more objec-
tive and standardized method is needed instead of the
subjective cytology. Over the last years it has been re-
ported (6–9) that the bladder tumor antigen (BTA)-
TRAK™ assay as well as the nuclear matrix protein
(NMP)22 assay could be clinically useful in mass
screening and in primary diagnosis to detect bladder
cancer in voided urine. We investigated these two as-
says to see whether they can replace cystoscopy or cy-
tology, respectively and whether they can improve ex-
isting diagnostic strategies.
Materials and Methods
Between 1997 and 2000 we investigated in a prospective
study the voided urine samples of 651 consecutive patients
undergoing cystoscopy. Clinical diagnosis was unknown at
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this time. As a control group we also examined urine of 24 pa-
tients with urinary tract infections and 30 healthy individuals,
without performing cystoscopy. We divided the collective into
seven groups: a) 30 healthy individuals, b) 24 patients with uri-
nary tract infections, c) 233 patients with benign urological
diseases (prostatic adenoma, benign prostatic hypertrophy,
condyloma, phimosis, incontinence, abscess, renal insuffi-
ciency, urethral stricture, urolithiasis, nephrolithiasis) d) 36
patients with urinary bladder cancer at primary diagnosis, e)
134 patients with relapse of the urinary bladder cancer (posi-
tive cytology or histology), f) 98 patients with bladder cancer
history but at the stage of no evidence of disease (NED) and g)
150 patients with other urological malignancies (111 with
prostate cancers, 29 with carcinoma of the kidney, 3 with col-
orectal cancers, 3 with testicular tumors, 3 with cancers of the
deferent urinary tract and 1 with cancer of the vagina). We
used the BTA-TRAK™ (Bard Diagnostics, Redmont, USA) and
NMP22 (Matritech, Newton, USA) enzyme-linked immunoas-
says. BTA-TRAK™ detects a complement factor H-related pro-
tein (CFH-rP) and the test itself is conducted in a series of small
wells (microtiter plates). The BTA test is an immunoassay that
uses two monoclonal antibodies to detect bladder tumor anti-
gen in urine samples. One antibody is used to capture the an-
alyte and the second antibody, which is conjugated to col-
loidal gold, serves as the reporter molecule, allowing the
visual detection of the analyte in the urine specimen. The nu-
clear matrix is a three-dimensional web of RNA and proteins
that provides the structural foundation for a cell’s nucleus. By
serving as an anchoring point for enzymatic machinery, nu-
clear matrix participates in DNA replication, transcription,
RNA processing and gene expression. NMPs undergo alter-
ation at different stages of cell replication. Various NMPs are
organ-specific. NMP22 is found in human epithelial cells and
is a component of a large complex known as the nuclear mi-
totic apparatus (NuMA), the function of which seems to be re-
lated to the distribution of genetic material during mitosis.
NuMA is known to be concentrated in urothelial cancer cells
with levels up to 25 times those of normal cells. Given this,
NMP22 was recognized as a potential urothelium-specific can-
cer marker. The NMP22 analyte is detected in a stabilized,
voided urine sample using an enzyme immunoassay in mi-
croplate format. Calibrators, controls and patients’ specimens
are detected in the microtiter plate using two monoclonal an-
tibodies specific for the NMP22 protein. Quantitative results
are reported as units of NMP22 per milliliter (U/ml).
Results
Methodological observations
The BTA-TRAK™ test method was quite satisfactory
with an intraassay variation of 6% (n = 8) and an in-
terassay variation between 4 and 18% (n = 5) for
reagent kit controls. We also found acceptable results
for NMP22 with an intraassay variation of 11% (n = 8)
and an interassay variation of 8.9% (n = 8) also for
reagent kit controls.
Clinical findings
Distribution of bladder cancer patients with regard to
grade and stage
In the active bladder cancer collective of 170 patients
we distinguished between primary diagnosis (36 pa-
tients) and recurrent disease (134 patients). By subclas-
sifying these groups into grades G1-3 we found 50%
(13/26) of the patients with a low differentiation grade
(G3) in the primary diagnosis category and only 28%
Table 1 Distribution of the values for BTA-TRAK TM and NMP22.
Marker Group n Median 95% Range Positive results [%]
percentile Manufacturer’s cut-off
true positive false positive
BTA-TRAK Healthy individuals 30 2.3 4.3 0.4–4.5 0
[U/ml] Urinary tract infection 24 95.8 1188 2.8–1863 75
Benign urological 233 10.2 1295 1.0–9370 43
diseases
Bladder cancer primary 36 131.0 8551 1.0–12318 78
diagnosis
Bladder cancer relapse 134 31.3 1866 1.0–10842 48
Bladder cancer NED 98 10.3 1600 0.9–3300 59
Cut-off BTA-TRAK: 14 U/ml
NMP22 Healthy individuals 30 4.2 7.72 2.1–8.6 0
[U/ml]
Urinary tract infection 24 10.5 87.4 0.01–206 54
Benign urological 233 5.3 71.5 0.001–650 28
diseases
Bladder cancer primary 36 13.7 761 1.4–826 50
diagnosis
Bladder cancer relapse 134 5.1 220 0.01–898 28
Bladder cancer NED 98 4.1 72.6 0.01–622 22
Cut-off NMP22: 10 U/ml
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(21/76) in the recurrent disease category. For primary
diagnosis, thus, high or moderate differentiation was
shown to be less prevalent (G1–23%, G2–27%) than
with recurrent disease (G1–24%, G2–49%). Tumor
staging resulted in no carcinoma in situ present in the
primary diagnosis category but 10 present in the re-
lapse category. In both groups most of the patients had
stage pTa (primary diagnosis category: 43%, relapse
category: 45%). However, 30% of the patients had tu-
mor stage > pT2 at the time of primary diagnosis com-
pared to only 8% at the relapse stage (Table 1).
Both assays showed low values for healthy individu-
als (BTA-TRAK™: < 4.5 U/ml, NMP22: < 9 U/ml). Patients
with urinary tract infection had a high concentration of
both analytes. In this group we found values up to ap-
proximately 1900 U/ml for BTA; for NMP22 the highest
measured value was 206.0 U/ml. There was a wide range
of values in all the groups for the BTA test (1.0–12318.0
U/ml). For NMP22, very high values (>650.0 U/ml) were
measured for active bladder cancer at primary diagnosis
or progressive disease. The median value for BTA, as an
example of the statistical distribution, showed that all
the groups investigated had considerably higher values
compared to healthy individuals (2.2 U/ml). For NMP22,
very high median values, compared to healthy individu-
als, were observed only in active bladder cancer at pri-
mary diagnosis (13.7 U/ml) and in urinary tract infection
(10.5 U/ml) (Table 2, Figures 1, 2, 3). Moreover, the BTA-
TRAK™ did not show any relationship to pT-stages.We
found widely spread values from tumor in situ stage to
pT4. NMP22 displayed the same pattern with regard to
staging with the exception of carcinoma in situ where
only low values (<10 U/ml) were observed. Regarding
disease grade, the BTA-TRAK™ assay did not reveal any
relationship, with high values present in stages G1-3.
The NMP22 test showed that all patients with grade
G1 had values below 22 U/ml; for grade G2 and G3, the
values were widely distributed.
Primary diagnosis
Seventy one percent of the bladder cancer patients
were referred to our clinic with hematuria being the
principal symptom at primary diagnosis but 72% of our
collective had hematuria, but no bladder cancer, when
they came to the hospital and thus were shown to be
false-positive. Also, 34% (69/203) of the patients with
benign urological diseases had hematuria. In 89% of
the patients cytology was positive at the time of pri-
mary diagnosis and in 52% at the relapse stage. Fur-
thermore, we compared the sensitivity of hematuria
with the sensitivity of both assays for the detection of
the active stage of disease and the specificity in benign
urological diseases by using a simple crosslab and the
manufacturers’ recommended cut-off values (NMP22:
10 U/ml, BTA-TRAK™: 14 U/ml). Forty eight percent of
Table 2 Distribution of hematuria, BTA-TRAK TM and NMP22
for urinary bladder cancer at active stage.
[%] [%] [%] [%]
NMP22 NMP22 BTA- BTA-
+ – TRAK TRAK
+ –
Hematuria Benign urological 17 19 28 5
+ disease
Active bladder 29 19 46 2
cancer
Hematuria Benign urological 11 56 16 51
– disease
Active bladder 12 40 22 30
cancer
Cut-off: NMP22: 10 U/ml, 
BTA-TRAK: 14 U/ml
Figure 1 Dot plot: distribution of the values for the BTA-TRAK™ test and the NMP22 test in various groups.
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patients with active bladder cancer (either primary di-
agnosis or relapse) had micro- or macroscopic hema-
turia at the time of hospitalization. NMP22 result was
true-positive in 41% and the BTA-TRAK™ test in 68% of
the cases. However, these results also mean that there
were 59% false negatives for NMP22 and 32% for BTA-
TRAK™, respectively (Table 3). By maintaining this pro-
cedure but considering patients with benign urological
diseases 36% came to the hospital with hematuria. At
this time, NMP22 was false-positive in 28% and BTA-
TRAK™ in 44% of the cases (Table 3). Following the
guidelines of the European Group on Tumor Markers
(10), as is usually done in our studies, we fixed speci-
ficity at 95% (6). First we used patients with benign uro-
logical diseases and urinary tract infections as one ref-
erence group and found 17% sensitivity for the BTA-
TRAK™ test (cut-off: 1200.0 U/ml), corresponding to
31% for the NMP22 test (cut-off: 75 U/ml) (Figure 4).
We then used healthy individuals as reference
group. With the same postulation (95% specificity) we
obtained a sensitivity of 89% for the BTA-TRAK™ test
(cut-off: 4.3 U/ml) compared to 61% for NMP22 test
(cut-off: 7.7 U/ml) for patients with bladder cancer at
primary diagnosis (Figure 5). In the next step we
wanted to find out whether sensitivity increases with
pT-staging. We used again the manufacturers’ cut-off
for BTA-TRAK™ (14 U/ml) and NMP22 (10 U/ml) and
calculated the true-positive results. Finally, we also
Figure 2 Distribution of the values for NMP22. healthy individuals (n=30); urinary tract infection (n=24);
benign urological disease (n=233); urinary bladder cancer (n=135).
Figure 3 Distribution of the values for BTA-TRAK™. healthy individuals (n=30); urinary tract infection (n=24);
benign urological disease (n=233); urinary bladder cancer (n=135).
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compared these findings with cytology (only malig-
nant cells were considered as positive results). The
BTA-TRAK™ test showed a high sensitivity for carci-
noma in situ with 80% and for pT1 81% but only 50% of
the superficial bladder cancers pTa were detected.
Worse sensitivity was found with the NMP22 assay:
carcinoma in situ 0%, pTa 18%, pT1 65% and > pT2 23%.
With cytology we gained quite acceptable results: car-
cinoma in situ 56%, pTa 74%, pT1 67% and > pT2 73%
(Table 3). Finally, we took a look at a possible depen-
dency on grade (G1-3). BTA-TRAK™ as well as NMP22
and cytology had an increasing sensitivity for decreas-
ing cell differentiation grade (Table 4). The best sensi-
tivity for high differentiation (G1) was found with cytol-
ogy (53%).
Follow-up care and relapse
We next investigated whether the assays are able to
discriminate between patients with no evidence of dis-
ease and patients with a recurrent bladder cancer in fol-
low-up care. Using 95% specificity for NED-patients,
we obtained 8% sensitivity for BTA-TRAK™ corre-
sponding to 12% with NMP22 in patients with relapse
(cut-off value: BTA-TRAK™: 1530.0 U/ml, NMP22: 58.0
U/ml).
To show the real power of discrimination between
patients with NED and patients with a relapse we used
Table 3 Distribution of BTA-TRAK TM, NMP22 and cytology
values with regard to stage and grade.
[%] [%] [%] [%] [%] [%] [%]
Stage/grade Tis TA T1 T≥2 G1 G2 G3
n 10 44 31 13 24 44 34
NMP22 0 18 65 23 13 28 52
>10 U/ml
BTA-TRAK 80 50 81 77 50 60 82
>14 U/ml
Cytology + 56 74 67 73 53 78 70
Figure 4 Specificity and sensitivity of hematuria, cytology,
BTA-TRAK™ and NMP22 for bladder cancer at primary diag-
nosis. Specificity vs. benign urological disease and urinary
tract infection, cut-off: BTA-TRAK 1200 U/ml, NMP22 75 U/ml.
specificity; sensitivity.
Figure 5 Receiver operating characteristic curves (ROC). Be-
nign urological diseases vs. bladder cancer at primary diagno-
sis and healthy individuals vs. bladder cancer at primary diag-
nosis. BTA-TRAK:  healthy individuals vs. urinary bladder
cancer;  benign urological disease vs. urinary bladder cancer;
 healthy individuals vs. urinary bladder cancer;  benign uro-
logical disease vs. urinary bladder cancer.
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the median value of healthy individuals (BTA-TRAK™:
2.3 U/ml, NMP22: 4.2 U/ml). By this means, we found
for patients with recurrent disease 92% true positives
with the BTA-TRAK™ assay and 63% with NMP22 but
still 8% false-negative results for BTA corresponding to
37% with the NMP22 test. For NED patients the BTA-
TRAK™ test revealed 85% true-negative results com-
pared to 49% with the NMP22 test, which also means in
turn 15% false-positive results were measured with
BTA-TRAK™ corresponding to 51% with NMP22.
Discussion
In our investigation we compared the BTA-TRAK™ as-
say with the NMP22 test both of which are supposed to
detect urinary bladder cancer in voided urine. The BTA-
TRAK™ test measures a CFHrP and thus revealed – as
also reported by other investigators – high values in all
the various groups whenever patients presented with
the symptom hematuria (11). NMP22 did not show this
phenomenon so often, although there have been pub-
lications which show an impact on urinary NMP22 (12).
Concerning bacterial infections, the BTA test showed
widely spread values especially in case of a urinary
tract infection with micro- or macroscopic hematuria.
In our collective NMP22 was strongly influenced by in-
fectious diseases of all kinds, although other investi-
gating groups suggested excluding all these patients
(5, 13). After extensive discussions with the specialists
of the Urological Department in our hospital we came
to the conclusion that if this was done, then not a lot of
patients would be left for the testing, since once a blad-
der has been treated with bladder cancer therapy (radi-
ation, chemotherapy, transurethral resection, bacillus
Calmette-Guerin instillation) then it will no longer be a
healthy organe anymore. Almost all of these patients
suffer from chronical or active cystitis. Boman et al. (14)
excluded these groups from their study (comparison of
four bladder tumor markers) and thus revealed a better
sensitivity (BTA stat 75%, NMP22 65%) than we did
(BTA-TRAK™ 17%, NMP22 31%). They used the quali-
tative BTA stat test to obtain a specificity (75%) that was
also used for the other tests to have a comparable situ-
ation for the calculation of sensitivity. Due to this speci-
ficity, NMP22 had a rather low cut-off value (4 U/ml). On
the basis of such influences and the difficult matrix –
urine – itself, it is not surprising that a discrimination
between the different diseases is impossible indepen-
dent of whether the sickness is benign or malignant.
For these reasons neither of these tests can never be of
clinical use in mass screening of high-risk patients. For
this indication we would have to postulate 100% speci-
ficity and 100% sensitivity for an assay to exclude false-
positive, but above all completely exclude false-nega-
tive results completely. With such an assumption we
would find results for both tests to be of no real value.
In a next step we wanted to show if the assays could
bring any help to already existing diagnostic methods
in primary diagnosis. In order to be able to compare
both tests’ findings with the gold standard “histology“
(specificity and sensitivity 100% each) we had two dif-
ferent reference groups at our disposal. Following the
guidelines of the European Group on Tumor Markers,
we fixed specificity at 95% (cut-off: BTA-TRAK™ 4.3
U/ml, NMP22 7.7 U/ml) for healthy individuals first. The
BTA test then had a sensitivity of 89% corresponding to
61% with NMP22. These results seemed to be very
promising especially for the BTA assay but we used – in
order to be comparable with other investigators –
healthy individuals as a reference group (15, 16). This
though does not reflect reality, it only shows the daily
routine to appear in a more positive light – as patients
present with symptoms! For this reason, patients with
benign urological diseases and/or urinary tract infec-
tions have to be the real reference group to determine
specificity for primary diagnosis. Using this as a basis
we found a completely different situation. In our collec-
tive cytology had 89% sensitivity. Understandably we
could not carry out specificity for it, as the urologists do
not take irrigation cytology from all patients (benign
urological diseases or urinary tract infections). But we
determined specificity for hematuria, the BTA-TRAK™
assay and NMP22 test; 66% of the patients had hema-
turia, the cardinal symptom of bladder cancer, at the
time of primary diagnosis, but 34% of the reference
group also had hematuria and thus were false positive.
By using now 95% specificity we found a sensitivity of
17% for the BTA test and for NMP22 31%. These results
can be demonstrated again with receiver operating
characteristic (ROC) curves to show the power of dis-
crimination between two comparative groups (Fig-
ure 5). Boman et al. maintained that pT-stage is differ-
ent when we compare primary diagnosis to recurrent
disease (14). With our investigation we can affirm this
statement. In our collective 57% of the patients were
staged with > pT1 at primary diagnosis compared to
41% at recurrence. This fact can be expected if patients
have regular follow-up care (e.g. every 3 months). In
our study we could not find any dependency on pT-
stage for the BTA-TRAK™ test with high values for all
stages. NMP22 showed the same pattern for the distri-
bution of the values with the exception of carcinoma in
situ with only low values (< 10 U/ml). It is desirable that
a diagnostic method should detect bladder cancer at an
early stage of disease before it grows invasive. There-
fore, we calculated sensitivity (true positive results) for
the BTA-TRAK™ test, NMP22 and cytology in depen-
dency on pT-staging for active bladder cancer (primary
diagnosis and recurrent disease). We used the manu-
facturers’ cut-off (BTA-TRAK™: 14 U/ml; NMP22: 10
U/ml). NMP22 had the worst sensitivity for low stages
with 0% for carcinoma in situ and 18% for pTa. The
BTA-TRAK™ test was superior with 50% for pTa and the
best sensitivity was found with cytology (74% for pTa).
Thus, we may ascertain as have other investigators
(14) that both assays are not useful for the detection of
early pT-stages for bladder cancer. Too many false-neg-
ative results would be measured. On this account, nei-
ther the BTA-TRAK™ assay nor NMP22 can replace
cystoscopy or cytology.
Further we tested the two assays as to whether they
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are able to distinguish between patients with NED and
relapsed disease. Again, we used 95% specificity for
NED patients and found a sensitivity for the BTA test of
8% and for NMP22 12% in relapsed disease (cut-off
value: BTA-TRAK™: 1530.0 U/ml, NMP22: 58.0 U/ml).
As the results were not satisfactory at all, we used the
median value of healthy individuals (BTA-TRAK™: 2.3
U/ml, NMP22: 4.2 U/ml) to show specificity and sensi-
tivity for the two assays. As NED patients are free of
disease, we have to consider them as healthy individu-
als. In 92% of patients with relapsed disease, BTA-
TRAK™ amounts to true positive results compared to
63% with the NMP22 test. On the other hand, though
we had false-positive results in 15% for BTA and in 51%
for NMP22 and that in turn could mean that unneces-
sary cystoscopies are carried out. These results are un-
satisfactory and this has also been ascertained by other
investigators (9). On the basis of our results, we con-
clude that there is not much hope thatboth tests can be
applied in the follow-up care of bladder cancer due to
the low specificity of the BTA-TRAK™ test (hematuria)
and the low sensitivity of NMP22.
Conclusion
Due to an insufficient specificity and sensitivity, both
tests cannot be of clinical utility neither in mass screen-
ing of high-risk patients nor in primary diagnosis of
bladder cancer. They cannot replace neither cys-
toscopy nor cytology. In the follow-up care more inves-
tigations may be necessary to prove a potential benefit
in existing diagnostic strategies, although we are not
really hopeful for it because of too many false-positive
results in inactive bladder cancer (NED) and, what is
more important, because of false-negative results in
the active stage of disease.
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